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Abstract
Background and objectives: The number of women of childbearing age with chronic diseases is rising. Evidence has
shown that obstetric complications and poor psychological well-being are more prevalent among this group, in
addition to these women reporting experiences of less than satisfactory care. More research is needed to investigate
how to best meet the special needs of this group during pregnancy and postpartum. Previous research has shown
that care coordination, continuity of care, woman-centered care, and specialized maternity care interventions delivered
to women with high-risk pregnancies can improve patient-reported outcomes and pregnancy outcomes and be cost-
effective. However, no previous trials have examined the efficacy and cost-effectiveness of such interventions among
pregnant women with chronic diseases. This paper describes the protocol of a randomized controlled trial (RCT) of a
midwife-coordinated, individualized and specialized maternity care intervention (ChroPreg) as an add-on to standard
care for pregnant women with chronic diseases.
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Methods/design: This two-arm parallel group RCT will be conducted from October 2018 through June 2020 at the
Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Denmark. Pregnant women with chronic
diseases are invited to participate; women will be randomized and allocated 1:1 to the ChroPreg intervention plus
standard care or standard care alone. The ChroPreg intervention consists of three main components: (1) coordinated
and individualized care, (2) additional ante- and postpartum consultations, and (3) specialized midwives. The primary
outcome is length of hospital stay during pregnancy and in the postpartum period, and secondary outcomes are
psychological well-being (five-item World Health Organization Well-Being Index, Edinburgh Postnatal Depression Scale,
Cambridge Worry Scale), health-related quality of life (12-Item Short Form Health Survey), patient satisfaction
(Pregnancy and Childbirth Questionnaire), number of antenatal contacts, and pregnancy and delivery outcomes. Data
are collected via patient-administered questionnaires and medical records.
Discussion: This trial is anticipated to contribute to the field of knowledge on which planning of improved antenatal,
intra-, and postpartum care for women with chronic disease is founded.
Trial registration: ClinicalTrials.gov, NCT03511508. Registered April 27, 2018.
Keywords: Pregnancy, Chronic disease, Midwifery, Maternity care, Antenatal care, Psychological well-being, Complex
intervention
Background
In Denmark and worldwide, the number of individuals
living with chronic disease is rising [1, 2], and more than
one in three Danish adults live with one or more chronic
diseases [1]. The management and prevention of chronic
disease is a worldwide major public health problem and
one of the issues most targeted by the World Health
Organization (WHO) [2].
The number of pregnant women affected by chronic
diseases such as autoimmune disease, cardiovascular
disease, and endocrine disease is also rising, in 2015,
the prevalence in Denmark was 16% among pregnant
women [3], and international studies report a preva-
lence between 16% and 27% [4, 5]. The observed rise in
chronic disease among pregnant women reflects the
rise in chronic disease in the general population [1].
Factors also contributing to this rise include the in-
creasing age of childbearing women, improvements in
medical and surgical treatment options, increased use
of assistive reproductive technologies, and improve-
ments in diagnostic challenges with better registration
of correct diagnoses [3, 6].
Pregnant women with chronic diseases are a vulner-
able group. Overall, these women have a higher risk of
preterm birth, pregnancy complications such as gesta-
tional diabetes and preeclampsia, operative deliveries,
postpartum depression, and longer hospitalization dur-
ing pregnancy and postpartum [5–9]. In addition to this,
children of women with chronic diseases have a higher
risk of low birth weight, low Apgar score, and birth
defects [10–12]. For some women, their chronic disease
may be worsened by pregnancy [13], whereas in other
cases of disease, women may experience remission from
symptoms during pregnancy [10, 14]. Furthermore, in
diseases such as sclerosis and rheumatoid arthritis, there
is an increased risk of postpartum flares [14–16].
In qualitative studies, women with chronic diseases
indicate that information given by caregivers can be un-
coordinated and divergent (e.g., information about medi-
cation safety, mode of delivery, and breastfeeding).
Women also described less than satisfactory care from
midwives and doctors in relation to discussing how to
distinguish symptoms of pregnancy and what relates to
the disease and to prepare women for what to expect
during pregnancy [16]. In addition to these experiences,
women described a general experience of “feeling aban-
doned” postpartum and how support for and under-
standing of their needs were lacking at the time of
discharge [17, 18].
The consequences of the increasing population of
pregnant women with chronic diseases are numerous,
including a higher demand on maternity care providers
to skillfully manage pregnancies complicated by chronic
diseases. Furthermore, this increase calls for all mater-
nity care providers to provide coordinated care and con-
sistent counseling [19–21] and to support the pregnant
woman in her ability to manage her everyday life with a
chronic disease both during pregnancy and postnatally
as a new mother [18]. It is therefore important that care
providers apply highly specialized medical knowledge
combined with an ability to provide psychosocial sup-
port in the care of this vulnerable group of pregnant
women [6, 16, 22].
Previous randomized controlled trial (RCTs) that
evaluated the effect of maternity care interventions for
women with high-risk pregnancies have found that the
following components had a positive effect on patient-
reported outcomes such as patient satisfaction and
de Wolff et al. Trials          (2019) 20:291 Page 2 of 12
health economic outcomes such as cost reduction and
reduction in length of hospital stay (LOS): implementa-
tion of specialized multidisciplinary teams [20, 21, 23],
care coordination [19, 24], continuity of care [25], ante-
natal and postpartum telephone-based support [26], and
maternity care with focus on care transitions [22]. In a
review of RCTs [22], the introduction of nurse specialist
care during pregnancy and the postpartum period of
pregnant women with epilepsy demonstrated a positive
effect on satisfaction of care provided and a reduction in
LOS. To our knowledge, no previous RCT has evaluated
the effect of the implementation of a midwife-coordinated,
individualized, and specialized maternity care intervention
as an add-on intervention to standard care delivered to
pregnant women with chronic diseases.
Aim
The aim of this RCT, the ChroPreg Trial, is to evaluate
the efficacy of a midwife-coordinated, individualized,
and specialized maternity care intervention as an add-on
to standard care for pregnant women with chronic dis-
eases. The primary outcome is LOS measured in days of
hospitalization from study inclusion until 2 weeks after
delivery. Secondary outcomes are patient-reported
psychological well-being, health-related quality of life,
satisfaction with care, antenatal contacts, and pregnancy
and delivery outcomes.
Hypothesis
The trial was designed to evaluate the effect of a
midwife-coordinated, individualized, and specialized ma-
ternity care intervention provided to pregnant women
with chronic diseases. We hypothesize that this complex
intervention with all its components will have a positive
impact on the self-reported psychological well-being of
the participants, increase health-related quality of life
and satisfaction with the care provided, and enhance the
participants’ ability to cope with everyday life during
pregnancy and in the immediate postpartum period. We
hypothesize that the sum of these components will
reduce the total number of days of hospitalization.
Previous trials with complex maternity care interven-
tions with nurse specialists and midwifery continuity-of-
care models have shown a reduction in LOS. Tracy et al.
[25] showed a mean reduction in LOS of 0.38 days (95%
confidence interval, 0.18–0.56) in the postnatal hospital
stay among a population of mixed-risk pregnant women
(n = 1748). We expect that the reduction in LOS will be
greater in this trial with a population of high-risk preg-
nant women with chronic disease. In addition, we will
measure LOS both antenatally and postpartum from the
time of inclusion and up until 2 weeks after delivery.
Methods/design
Study design
The ChroPreg trial is a two-arm parallel-group investigator-
initiated RCT. Participants will be randomized to either a
midwife-coordinated, individualized, and specialized mater-
nity care intervention (ChroPreg) as an add-on intervention
to standard care or standard care alone with a 1:1
allocation. The trial is designed in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines for RCTs [27], extended in the better reporting
of interventions: Template for Intervention Description and
Replication (TIDieR) checklist and guide [28] (Additional
file 1), and in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guide-
lines for reporting trial protocols [29] (Additional file 2).
Study setting
The study will take place at the Department of Obstet-
rics, Copenhagen University Hospital, Rigshospitalet,
Copenhagen, Denmark. The department is highly
specialized and in addition to serving as a birth facility
for women living in the local area of the hospital in
Copenhagen, it is a tertiary referral center for a large
geographical area. In 2017, 5471 women gave birth at
the hospital, and 700 of these women had one or more
chronic diseases. Participants will be recruited from
among the women attending antenatal care at Rigshospi-
talet. In Denmark, all women with normal pregnancies
receive antenatal care primarily from midwives, whereas
pregnant women with chronic disease and complicated
pregnancies receive obstetrician-led antenatal care, in-
cluding consultations with midwives.
Inclusion and exclusion criteria
The Danish Health Authorities define chronic disease as
a prolonged disease or a disease that continually recurs
[30]. Eligible participants will be pregnant women with
one or more chronic diseases diagnosed before preg-
nancy and for which the pregnant woman is followed by
an obstetrician during pregnancy, aged ≥ 18 years, able
to understand spoken and written Danish, give informed
consent, pregnant with a single live fetus, and be
between weeks 12 and 19 of pregnancy at the time of
inclusion. Potential participants will be excluded from
the study for the following reasons: multiple pregnancy,
substance abuse, psychiatric disease as the only chronic
disease, and pregnant women with diabetes and heart
disease (these women already receive specialized care
programs at Rigshospitalet).
Recruitment procedure
As a part of the standard antenatal care contacts,
women who fulfill the study criteria will be invited to
participate in the study by a midwife from the antenatal
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clinic responsible for the coordination of specialized
antenatal care. Eligible participants who verbally consent
to receive more information about the study will be
given written information and subsequently contacted
by telephone by one of the investigators. If the woman is
still interested in receiving information about the study,
preliminary questions will be answered. Thereafter, the
woman is given the choice between having a face-to-face
meeting at the hospital or receiving additional informa-
tion by telephone. At the face-to-face meeting or during
the telephone conversation, more detailed verbal infor-
mation about the study will be provided by one of the
investigators, and the potential study candidate will have
the opportunity to ask further questions about the study.
If the woman decides to participate, written informed con-
sent will be obtained by the investigator, and the baseline
questionnaire will be completed. The randomization and
allocation to one of the two RCT arms will be carried out
by one of the investigators. The choice between mode of
receiving information, either by telephone or face-to-face,
is done to accommodate women who do not live near the
hospital or have other reasons to prefer receiving informa-
tion by telephone. A Danish RCT study tested the effect of
face-to-face versus telephone information when including
study participants and found no differences in level of
comprehension between the two groups [31].
Randomization and blinding
After informed consent is obtained, participants are ran-
domized by one of the investigators to either the Chro-
Preg intervention plus standard care or standard care
alone in a ratio of 1:1. The allocation sequence is
computer-generated and nonstratified with varying block
sizes concealed to the researchers. The allocation will be
centrally conducted using the EasyTrial online clinical
trial management and randomization system (easytrial.
net, Aalborg, Denmark). After allocation, the partici-
pants will be informed about the allocation and further
plan of the trial.
The specialized midwives (SM) who will deliver the
intervention will not be blinded to the allocation, and
neither will the participants. However, the research
staff who will collect data from medical records and
questionnaires will be blinded to treatment allocation,
as will the chief investigator (HKH) and the trial statis-
tician (SR).
Sample size calculation
A total of 258 women will be enrolled in the study. The
sample size was determined using unpublished data on
426 pregnant women with chronic diseases hospitalized at
Rigshospitalet during pregnancy and in the postpartum
period in 2017. The average LOS during pregnancy was
3.9 days; however, due to a right-skewed distribution, log-
transformed LOS was used as the outcome for the sample
size calculation. Therefore, the effect of the intervention is
expressed as a ratio. We expect a reduction of 25% in LOS
in the intervention group compared with the control
group. This corresponds approximately to a mean reduc-
tion of 1 day of hospitalization and to an improvement of
log (1 – 0.25) = − 0.29 on the logarithmic scale, which we
consider a realistic and clinically significant effect size.
The standard deviation (SD) of number of days in the hos-
pital on a logarithmic scale was 0.80. With a difference of
0.29 and SD of 0.80, a power of 0.8, and a significance
level of 0.05, an analysis by two-sample t test requires 123
women in each group. We expect a maximum of 5% to be
lost to follow-up, leading to a total of 129 women needed
to be enrolled in each group (Fig. 1).
Intervention
Standard care alone
Participants allocated to the control group will receive
standard care alone. Pregnant women with chronic dis-
ease are considered to have high-risk pregnancies and
are referred to the appropriate level of specialized mater-
nity care. All pregnant women with chronic disease will
be followed by an obstetrician, and an individual care
plan is designed considering the character and severity
of the disease and the pregnancy-associated risks. Rou-
tinely in Denmark, all pregnant women, including preg-
nant women with chronic diseases, are also followed by
midwives during pregnancy. The standard care appoint-
ments for midwife consultation are timed approximately
around weeks 14–18, 28, 35, 38, and 40 and include
physical examinations, discussion about lifestyle, symp-
toms of normal and complicated pregnancies, breast-
feeding, and preparation for delivery. At Rigshospitalet,
two auditorium prenatal classes (90 min each) are deliv-
ered by a midwife. The classes provide information
about what to expect during birth (contractions, pain
relief, possible complications, and interventions) and in
the puerperium (breastfeeding and family building).
After childbirth, women can contact the department and
request a conversation about the delivery with a midwife,
and women who have experienced severe or unexpected
complications may be offered a postnatal consultation
with an obstetrician.
ChroPreg intervention plus standard care
The ChroPreg intervention is designed on the basis of a
review of the literature on complex interventions in
maternity care [19–21] and is aimed to fit the needs of
women with chronic disease. Complex interventions
[32] consist of a number of components that may work
independently and interdependently, and it can be
difficult to identify the “active ingredient” of the
intervention, rendering it even more important to
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describe the different components, the hypothesized
mechanism behind each component, and the interaction
between the components [32]. The three main compo-
nents of the ChroPreg intervention are described in more
detail below.
The ChroPreg intervention is provided by SM. In
addition to the standard care outlined above, women in
the intervention group will receive additional antenatal
consultations, postpartum follow-up, and care coordin-
ation. Both standard care midwife consultations and the
extra consultations will be provided by the same SM
(content described below and in Table 1).
Midwife-coordinated and individualized care The
participant will be seen by the same SM throughout the
study period. For all women in the intervention group,
the number of consultations covered by the SM will be
recorded. During the study period, the SM will identify
the special needs and wishes of each woman and will
discuss the optimal care of the woman with the obstetri-
cian responsible for her medical care. The SM will assist
the participants in coordinating antenatal visits to fit
their everyday life and to avoid unnecessary hospital
visits, as well as in communicating with other care pro-
viders who are part of the standard Danish health care
Fig. 1 The expected flow diagram of progress through the ChroPreg trial
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Table 1 Description of planned midwife activities in the ChroPreg intervention group and standard care group
ChroPreg intervention + standard care Objective of activity Standard care alone Objective of activity
During pregnancy
Weeks 14–18
Midwife appointment
30 min
Specialized midwife (SM)
At the hospital
Medical history taking,
follow-up on information
from general practitioner
Weeks 14–18
Midwife appointment
30 min
Regular midwife (RM)
At the hospital
Medical history taking,
follow-up on information
from general practitioner
Weeks 20–24
Midwife appointment
60 min
SM
At the hospital
Focus on psychological
well-being during pregnancy
and preparation for breastfeeding.
The consultation will be
centered on the woman’s
experience of pregnancy, physical
development, prenatal attachment,
the interaction between pregnancy
and chronic disease, normal pregnancy
signs and symptoms, and thoughts
about breastfeeding.
Weeks 28–30a
Midwife appointment
30 min
SM
At the hospital
Conversation about breastfeeding,
rhesus prophylaxis, well-being, and
symptoms of pregnancy and
chronic disease.
Weeks 28–30
Midwife appointment
30 min
RM
At the hospital
Conversation about
breastfeeding,
rhesus prophylaxis, well-being,
and symptoms of pregnancy
Weeks 30–33
Midwife appointment
60 min
SM
At the hospital
Focus on individual childbirth
preparation and postpartum care.
Information about birthing options
and pain relief and management.
The individual needs and wishes of
the woman will be discussed, and an
individual birth plan will be made.
Weeks 35–36
Midwife appointment
30 min
SM
At the hospital
Consultation about pregnancy,
well-being, symptoms of chronic
disease, and the coming birth.
Weeks 35–36
Midwife appointment
30 min
RM
At the hospital
Consultation about pregnancy
and the coming birth,
and well-being.
Weeks 38–39
Midwife appointment
30 min
SM
At the hospital
Consultation about pregnancy,
well-being, symptoms of chronic
disease, the coming birth, and
postpartum care and follow-up.
Weeks 38–39
Midwife appointment
30 min
RM
At the hospital
Consultation about pregnancy,
coming birth, and postpartum care
Week 40
Midwife appointment
30 min
SM
At the hospital
Consultation about coming birth,
pregnancy, and signs of labor,
discussion about induced labor
Internal vaginal examination if
woman wishes
Week 40
Midwife appointment
30 min
RM
At the hospital
Consultation about coming
birth, pregnancy, and signs of
labor; discussion about
induced labor
Internal vaginal examination
if woman wishes
Postpartum follow-up
First and second weeks
after discharge from hospital
30–60 min
SM
Telephone
Postpartum follow-up on
breastfeeding, chronic disease
management, medication, and
psychological well-being.
Coordination with primary health
care workers if needed (general
practitioner/health visitor/medical
specialists).
First week after
discharge from hospital
The woman can contact the
hospital with questions and
need for postpartum check-up.
4–6 weeks postpartum
60 min
Midwife appointment
SM
At the hospital/telephone
(woman’s choice)
This visit is arranged for the woman
to have the opportunity to discuss
her experiences of pregnancy and
childbirth with the SM.
The midwife will have the medical
records available, but the focus is on
allowing the woman to talk about and
elaborate on her experience. If the
midwife and the woman identify a
After discharge
from hospital
The woman can contact the
department for an appointment
to discuss experiences of
pregnancy and childbirth.
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system (e.g., general practitioner and health visitor) as
well as other health care professionals from other de-
partments at the hospital. The participants can contact
the SM by e-mail and during weekly phone hours. If the
participant is hospitalized during pregnancy, the SM will
contact the woman by phone and arrange an appoint-
ment. Assisting the participants when in labor is not a
part of the intervention.
Additional ante- and postpartum consultations In
addition to standard care, two additional antenatal con-
sultations will be scheduled with the SM at 20–24 weeks
and 30–33 weeks of pregnancy to discuss psychological
well-being in pregnancy, breastfeeding, individualized
preparation for childbirth, and postpartum care. The
purpose is to support the woman’s own capacity to han-
dle her pregnancy, childbirth, and everyday life as a new
mother with a chronic disease. If the need arises, the SM
can refer the woman to a psychologist at the hospital for
additional consultation. After birth, the SM follows up
with the woman regarding psychological well-being dur-
ing the planned telephone support postpartum, and 4–6
weeks after birth, a consultation is planned with the SM
to discuss the woman’s overall experience and issues im-
portant to the woman regarding her pregnancy and
delivery.
Specialized midwives Before initiation of the study, the
SM will have all attended a 3-day training delivered by
medical specialists from the hospital handling the care
for pregnant women with various chronic diseases. The
training includes medical knowledge on systemic lupus
erythematosus, rheumatoid arthritis, lung disease, kidney
disease, hypertension, multiple sclerosis, epilepsy and
other neurological diseases, inflammatory bowel disease,
hematological diseases, and thyroid disease. Additional
topics in the training program are prepregnancy coun-
seling, pathophysiology, pregnancy complications, symp-
toms of disease in relation to pregnancy, obstetric
treatment, medication and drug safety, lactation, and
interdisciplinary collaboration. The training also includes
psychological aspects of pregnancy complicated by
chronic disease. Topics covered are psychological devel-
opment during pregnancy, signs and symptoms of de-
pression and anxiety during pregnancy and postpartum,
prenatal attachment, and facilitating conversations about
the woman’s experience of childbirth. This part of the
training is delivered by midwives with further education
in psychology and by clinical psychologists. A manual
that outlines the content of all consultations with the
SM and topics covered during the consultations will be
developed and used as a tool by the SM. To secure inter-
vention fidelity, observations of the SM consultations
are carried out by one of the investigators in order to
give feedback.
Outcome measures
Data will be collected from medical records and elec-
tronic self-administered questionnaires and will be ob-
tained at baseline (t1) and three times during the study
period: at 33–37 weeks of gestation (t3), at 2 weeks after
delivery (t4), and at 2 months after delivery (t5) (Fig. 2).
The participants will complete the first electronic ques-
tionnaire after signing the informed consent to partici-
pate and before randomization. The subsequent
questionnaires will be sent as a link in an e-mail.
Primary outcome
The primary outcome is LOS measured as the number
of days (mean and SD) spent in the hospital from
Table 1 Description of planned midwife activities in the ChroPreg intervention group and standard care group (Continued)
ChroPreg intervention + standard care Objective of activity Standard care alone Objective of activity
need for further counseling, referral can
be made to a psychologist.
Activities throughout
the study period
E-mail correspondence
From inclusion to end
of study period
SM
The woman can contact the SM by
e-mail. This contact may concern all
relevant issues during pregnancy
and postpartum.
E-mail correspondence No e-mail correspondence
included.
Women can contact the
coordinating midwife department
with questions and concerns
Weekly telephone hours
From inclusion to end
of study period
SM
One day each week, the SM will be available
for telephone consultation as a supplement
to the planned face-to-face consultations.
Participants can call the midwife with
questions or concerns. The midwife will
evaluate if further visits will be needed in
addition to the telephone contacts.
Telephone
correspondence
Women can contact the
coordinating midwife department
with questions and concerns.
aAll standard midwife appointments from week 28 onward include urine testing for glucose and protein and measuring of blood pressure (screening for
indicators for gestational diabetes and preeclampsia) and physical examinations (measuring the size, heartbeat, and position of the fetus)
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Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram showing time points of enrollment, intervention, and outcome measures
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inclusion in the study and until 2 weeks after delivery.
All participants are expected to have a minimum of 1
day of hospital stay in relation to the delivery, because
this population is a high-risk population in which home
birth is advised against. Should a woman nevertheless
have an unplanned home birth, she will expectedly be
transferred to the hospital for postpartum.
LOS was chosen as the primary outcome because it is a
widely used outcome in health care research [33, 34]. For
this trial, a reduction in LOS covers at least two important
outcomes in health care research: (1) the patient perspective
with a reduced need for hospitalization, which is an expres-
sion of better quality of health care received by the patients,
and (2) the health economics perspective with reduced
health care costs in connection with days of hospitalization.
Secondary outcomes
Psychological well-being
1. Five-item WHO Well-Being Index (WHO-5) [35]
measures current (e.g., preceding 2 weeks)
psychological well-being and consists of five
positively phrased items, each scored on a Likert
scale (0 = none of the time, 5 = all the time). The
raw score ranges from 0, indicating the lowest
possible well-being, to 25, indicating the highest
possible well-being. This score is multiplied by a
factor of 4, creating a score ranging from 0 to
100, with 100 being the highest possible well-
being. WHO-5 has high psychometric validity,
and it can be used as an outcome measure in
clinical trials [35].
2. Edinburgh Postnatal Depression Scale (EPDS) [36] is
a self-reported scale consisting of ten items scored
on a 4-point Likert scale (0–3) concerning intensity
of depressive mood and symptoms during the last 7
days (0 indicates absence of depressive mood and/
or symptoms, and 3 indicates the worst mood and/
or symptoms on a given item). The lowest overall
score is 0, and the highest overall score is 30 (cutoff
scores included will be ≥ 10 and ≥ 13) [36, 37]. The
EPDS has been validated for use as a detection tool
for antenatal and postnatal depression [37, 38], and
it has been translated into Danish [39].
3. Cambridge Worry Scale (CWS) [40] measures
pregnant women’s degree of worry during
pregnancy. The questionnaire consists of 16 items
concerning different areas of possible worry on a 6-
point Likert scale (0 = no worry, 5 = highest degree
of worry). The scale ranges from 0 to 60, with 60
indicating the highest possible level of worry. CWS
has a high internal validity and reliability and has
been used in clinical studies including populations
of women with high-risk pregnancies [41, 42].
Health-related quality of life and self-rated health
SF-12 [43] is an abridged version of the 36-item Short
Form Health Survey developed to measure health-
related quality of life and thereby self-rated health in a
single item. The instrument is well-validated and reliable
and is widely used, including during pregnancy and in
the postpartum period [43, 44] . The SF-12 question-
naire consists of 12 items that measure physical and
mental health, divided into eight subscales: physical and
social functioning, role limitation due to physical and
mental health, bodily pain, general health perceptions
(self-rated health), vitality, and mental health. The scores
derived from the subscales can be calculated in two
overall scores—Physical Component Summary and
Mental Component Summary—with higher scores indi-
cating better health-related quality of life [43].
Patient satisfaction The Pregnancy and Childbirth
Questionnaire (PCQ) [45] contains two subscales: (1)
pregnancy-related items (18 items) covering two domains
(personal treatment and patient education/information)
and (2) birth-related items (7 items). The PCQ consists of
25 items rated on a 5-point Likert scale (1 = totally agree, 5
= totally disagree). Higher scores indicate higher patient sat-
isfaction with quality of care. The questionnaire has been
rated to have good internal consistency and reliability [46].
Health economic outcomes Antenatal contacts will be
measured as number of scheduled and unscheduled
visits with obstetric doctors and midwives and telephone
consultations.
Pregnancy and delivery outcomes Pregnancy and deliv-
ery outcomes will be measured as pregnancy complications
(gestational diabetes, pregnancy-induced hypertension, pre-
eclampsia) (yes/no), labor onset (spontaneous or induced),
preterm delivery (yes/no), mode of delivery (percentage of
participants with spontaneous vaginal delivery or cesarean
section [planned or emergency]), use of labor analgesia (no
analgesia/any analgesia, epidural analgesia [yes/no]), out-
patient telemonitoring for pregnancy complications (yes/no
and duration [days]), newborn’s well-being at time of deliv-
ery (Apgar score ≤ 7 at 5min postpartum [yes/no]), new-
born’s birth weight (measured in kilograms), breastfeeding
(intention to breastfeed [yes/no], breastfeeding 2 months
after delivery [yes/no], and intended duration [in months]
of breastfeeding).
Data analysis
Analyses are to be performed on the basis of the
intention-to-treat principle. The log-transformed number
of days in the hospital in the two groups will be compared
in the primary unadjusted analysis, and in a secondary
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analysis, adjustments will be made for parity and age. Ana-
lysis will be performed using the general linear model un-
less we find a generalized linear model (e.g., Poisson or
negative binomial) to fit the distribution of the number of
days in the hospital. Furthermore, the two groups will be
compared with respect to the proportion of women with 3
or fewer days in the hospital. Comparison of secondary
and exploratory outcomes will similarly be performed
using the general or generalized linear models as appro-
priate. In case of an uneven allocation of pregnancies with
congenital malformations or chromosomal abnormalities
to the two groups, analyses will be performed in the sub-
group of women without pregnancies with congenital
malformations or chromosomal abnormalities.
Discussion
The WHO estimates that chronic disease is the cause
of the majority of premature deaths in the world and
that most of these could be prevented by giving people
better access to appropriate health care and treatment
and by reducing modifiable risk factors such as diet,
exercise, and smoking [2]. Worldwide, the proportion
of women of childbearing age living with one or more
chronic diseases is growing [3, 5], and pregnancies
affected by chronic disease are associated with a higher
risk of complications [6, 10] and poor psychological
health [8, 47].
The perinatal period is theoretically a favorable time in
a woman’s life to implement effective preventive and
health-promoting interventions in women [48]. Inter-
ventions delivered in the perinatal period can therefore
hypothetically reduce the potentially negative health
impact in pregnancy caused by chronic disease and
possibly also empower and strengthen the women’s
long-term self-care ability with their chronic disease.
The ChroPreg trial is highly relevant, and to the best
of our knowledge, it is the largest RCT designed to
investigate the effect of a midwife-coordinated, individ-
ualized, and specialized maternity care add-on inter-
vention for pregnant women with chronic diseases on
LOS, patient-reported outcomes, and pregnancy and
delivery outcomes.
Systematic reviews of RCTs have found previous com-
plex maternity care interventions to be cost-effective com-
pared with standard care [24, 25]. However, in these
reviews, the authors have called for trials that evaluate
psychological well-being and patient satisfaction with
maternity care with validated psychometric instruments
[19, 49]. Therefore, in this RCT, we will use validated
patient-reported questionnaires to estimate psychological
well-being during pregnancy and postpartum [35, 36, 40],
health-related quality of life [43], and patient satisfaction
with maternity care [45].
In this trial, we will also combine face-to-face consul-
tations with add-on telephone support and e-mail
correspondence delivered by the SM who follow the par-
ticipants throughout pregnancy and postpartum. Tele-
phone support during pregnancy and after birth has
been suggested to be of benefit to women at risk of de-
pression, reducing signs of depression and facilitating
breastfeeding initiation and continuation [26]. However,
these interventions have not yet been tested among
pregnant women with chronic diseases, and therefore
the results of this trial may provide information on how
to design future woman-centered and cost-effective in-
terventions for women with chronic disease. This trial
will also provide information to clinicians about the
feasibility of prolonging midwifery care with consulta-
tions and more thorough follow-up after discharge from
the hospital, because this care currently is delivered pri-
marily by health visitors in Denmark.
Because this is a low-risk intervention adding to stand-
ard care and not involving any known side effects, we
anticipate that most eligible women with chronic disease
will be interested in participating in the trial, and we do
not expect a high number of dropouts. Measures to
monitor and enhance adherence to the intervention will
be taken. The two self-reported questionnaires, one at
33–37 weeks of pregnancy and one at 2 months postpar-
tum, will be followed by reminders if not completed
within the time frame, and text message reminders will
be sent in advance; adherence to all planned activities of
the interventions will be monitored and recorded. The
primary outcome (LOS) data are collected from medical
records and do not rely on patient self-reporting. To
reduce the risk of selection bias, eligible women will be
offered the choice between a face-to-face meeting and a
telephone conversation for information about the study,
informed consent, and randomization, accommodating
women living farther from the hospital.
The ChroPreg trial will provide an extensive evaluation
of a coordinated, individualized, and specialized mater-
nity care intervention for pregnant women with chronic
diseases. This trial will be among the first of its kind and
will help clinicians and policy makers to make evidence-
based decisions when developing and implementing effi-
cient, woman-centered, and cost-effective maternity care
interventions for women with chronic disease.
To conclude, this paper outlines the background,
aim, and methods of an RCT in which the ChroPreg
intervention plus standard care is compared with stand-
ard care alone in a population of pregnant women with
chronic disease. We hypothesize that the sum of active
components in the ChroPreg intervention will reduce
the overall need for hospitalization and enhance the
psychological well-being and satisfaction with care for
the participants.
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Trial status
Recruitment of participants was initiated October 1, 2018,
and is anticipated to continue until January 31, 2020, and
data collection will be concluded by June 1, 2020. By May
22 2019, 130 participants have been included in the Trial.
No interim analyses will be performed.
Additional files
Additional file 1: TIDieR checklist. (PDF 447 kb)
Additional file 2: SPIRIT checklist. (DOC 122 kb)
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